THE PROGNOSTIC VALUE OF INFLAMMATORY BIOMARKERS FOLLOWING TRAUMATIC BRAIN INJURY

S. A. Sharifbaev,
E. A.Vasilevsky,
O. T. Dadabaev,
N. G. Kamalov
Andijan State Medical InstituteAndijan, Uzbekistan

Introduction

Traumatic Brain Injury (TBI) is a major global health issue, representing a leading cause of mortality and long-term disability, particularly among young adults. The pathophysiology of TBI is not limited to the initial mechanical impact; rather, it triggers a cascade of secondary events that evolve over hours, days, and even years. These secondary injury mechanisms are often the primary determinants of a patient's long-term neurological outcome. Central to this secondary cascade is **neuroinflammation**, a complex and prolonged immune response within the central nervous system (CNS). Understanding the molecular and cellular drivers of this process is critical, and the identification of specific **biomarkers** of neuroinflammation offers a promising avenue for improving diagnostics, prognostic accuracy, and the development of targeted therapies for TBI patients **[1, 5]**.

The Secondary Injury Cascade and the Initiation of Neuroinflammation. The primary injury in TBI, resulting from direct mechanical forces, initiates a devastating series of secondary pathological events. One of the earliest and most critical processes is excitotoxicity, driven by the massive release of the neurotransmitter glutamate from damaged neurons. This leads to the overactivation of glutamate receptors, causing an influx of calcium ions into surrounding cells. This calcium overload triggers mitochondrial dysfunction, activates degradative enzymes, and promotes oxidative stress, culminating in delayed cell death through apoptosis and necrosis [1].

In this environment of cellular distress, dying cells release endogenous molecules known as Damage-Associated Molecular Patterns (DAMPs). Molecules such as high-mobility group box 1 (HMGB1) protein, ATP, and mitochondrial DNA act as powerful "danger signals" for the brain's resident immune cells. The recognition of these DAMPs by pattern recognition receptors (PRRs), like Toll-like receptors (TLRs) on microglia, serves as the primary trigger for the innate immune response and the onset of neuroinflammation [4].

The Role of Innate and Adaptive Immunity. Microglia, the primary immune cells of the CNS, are the first responders to injury. Upon activation by DAMPs, they transform from their resting, ramified state into an amoeboid, phagocytic form. This activation is not monolithic; microglia can polarize into different functional phenotypes. The classical M1 phenotype is pro-inflammatory, releasing cytotoxic substances like tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and reactive oxygen species, which can exacerbate neuronal damage. In contrast, the alternative M2 phenotype is associated with anti-inflammatory functions and tissue repair, releasing factors like IL-10 and transforming growth factor-β (TGF-β) [3]. The balance between M1 and M2 polarization is a critical determinant of the overall impact of neuroinflammation.

A crucial component of the secondary injury is the disruption of the blood-brain barrier (BBB). This complex cellular barrier, which normally protects the brain, is compromised by both the initial mechanical force and the subsequent release of inflammatory mediators. Increased BBB permeability allows for the infiltration of peripheral immune cells, including neutrophils, monocytes, and lymphocytes, into the brain parenchyma. This influx marks the engagement of the adaptive immune system. T-lymphocytes, upon recognizing CNS antigens, can contribute to both neurodegeneration and, potentially, to recovery processes, highlighting the dual-edged nature of the post-traumatic immune response [2].

Key Biomarkers of Neuroinflammation and Their Prognostic Value. The dynamic changes in the concentrations of inflammatory mediators in cerebrospinal fluid (CSF) and blood provide a valuable source of biomarkers for assessing injury severity and predicting patient outcomes.

Interleukin-6 (IL-6) - This pleiotropic cytokine is one of the most consistently elevated inflammatory markers following TBI. High levels of IL-6 in both CSF and serum have been strongly correlated with injury severity, increased intracranial pressure, and poor long-term neurological outcomes, including mortality. However, its utility can be limited by its low specificity, as systemic injuries can also cause a surge in IL-6 [5].

Interleukin-8 (IL-8) - As a potent chemokine, IL-8 is crucial for recruiting neutrophils to the site of injury. Studies have shown that elevated plasma levels of IL-8 within the first 24 hours post-injury are a robust predictor of mortality and unfavorable outcomes. Its correlation with intracranial hypertension makes it a particularly valuable marker for monitoring secondary complications [5].

Interleukin-10 (IL-10) - This is a key anti-inflammatory cytokine that functions to suppress the pro-inflammatory response. Its levels rise following TBI, likely as a compensatory mechanism. Paradoxically, very high levels of IL-10 are also associated with severe injury and increased mortality, possibly reflecting a state of profound immunosuppression. IL-10 has also demonstrated utility in distinguishing between complicated and uncomplicated mild TBI [5].

Tumor Necrosis Factor-α (TNF-α) - A major pro-inflammatory cytokine, TNF-α contributes to BBB breakdown, activates apoptosis, and can drive neurodegeneration. Elevated concentrations after TBI are associated with worse outcomes and the development of cerebral edema.

The long-term consequences of chronic, unresolved neuroinflammation are severe, with compelling evidence linking a history of TBI to an increased risk of developing neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease later in life [8].

Conclusion

Neuroinflammation is a fundamental and defining feature of the pathophysiology of Traumatic Brain Injury. The intricate interplay between innate and adaptive immune cells, orchestrated by a complex network of cytokines and chemokines, dictates the balance between secondary tissue damage and endogenous repair. Inflammatory biomarkers such as IL-6, IL-8, and IL-10 have emerged as powerful tools that offer objective insights into injury severity and help predict clinical outcomes. Future research must continue to refine our understanding of these pathways to develop novel therapeutic strategies aimed at modulating the immune response. Such interventions, potentially including cytokine inhibitors or therapies promoting a pro-reparative microglial phenotype, hold the promise of mitigating secondary brain injury and significantly improving the long-term functional recovery of patients [7].

References

1. Ladak A.A., Enam S.A., Ibrahim M.T. A Review of the molecular mechanisms of traumatic brain injury // World Neurosurg. — 2019. — Vol. 131. — P. 126-32. — doi:10.1016/j.wneu.2019.07.039.
2. Cash A., Theus M.H. Mechanisms of Blood-Brain Barrier Dysfunction in Traumatic Brain Injury // Int. J. Mol. Sci. – 2020 – Vol. 21. - P. 3344.
3. Definition of a mouse microglial subset that regulates neuronal development and proinflammatory responses in the brain / X. Shen, Y. Qiu, A. E. Wight, [et al.] // Proc. Natl. Acad. Sci. USA. – 2022. – Vol. 119, № 8. – P.e2116241119.
4. HMGB1 Inhibition to Ameliorate Organ Failure and Increase Survival in Trauma / Z. Yang, M. O. Simovic, P. R. Edsall, [et al.] // Biomolecules. – 2022. – Vol. 12, № 1. – P. 101.

5. Rodney T., Osier N., Gill J. Pro- and anti-inflammatory biomarkers and traumatic brain injury outcomes: A review // Cytokine. — 2018. — Vol. 110. — P. 231-237. — doi:10.1016/j.cyto.2018.02.001.
6. Jassam Y.N., Izzy S., Whalen M. et al. Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift // Neuron. – 2017 – Vol. 6. - P.1246–1265.
7. Putatunda R.B., Wenhui J.H. Potential immunotherapies for traumatic brain and spinal cord injury // Chinese Journal of Traumatology. – 2018 – Vol. 21. - P. 125–136.
8. Brett B.L., Gardner R.C., Godbout J. et al. Traumatic Brain Injury and Risk of Neurodegenerative Disorder // Biol. Psychiatry. – 2022 – Vol. 9, № 5. - P. 498–507.